Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation

Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation

<b>Background</b>: Therapeutic/intermediate-dose heparin reduces the risk of thromboembolic events but increases the risk of major bleeding in patients hospitalized for acute COVID-19 pneumonia. <b>Objectives</b>: To prospectively assess the incidence of objectively proven ve...

Full description

Bibliographic Details
Main Authors:	Francesco Poletto, Luca Spiezia, Chiara Simion, Elena Campello, Fabio Dalla Valle, Daniela Tormene, Giuseppe Camporese, Paolo Simioni
Format:	Article
Language:	English
Published:	MDPI AG 2022-03-01
Series:	Viruses
Subjects:	venous thromboembolism COVID-19 prophylactic-dose anticoagulation
Online Access:	https://www.mdpi.com/1999-4915/14/4/737

Similar Items

Does carbapenem-resistant enterobacteriaceae infection drive venous thromboembolism in patients admitted to intensive care units receiving prophylactic anticoagulants?
by: Fahad A S. Aleidan, et al.
Published: (2022-01-01)

Venous Thromboembolism in Hospitalized Critical and Noncritical COVID-19 Patients: A Systematic Review and Meta-analysis
by: Eman M. Mansory, et al.
Published: (2021-07-01)

Efficacy of the bleeding risk scoring system for optimal prophylactic anticoagulation therapy of venous thromboembolism in trauma patients: a single-center, retrospective, observational cohort study
by: Atsushi Tomizawa, et al.
Published: (2023-12-01)

Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project
by: Cristiano Bortoluzzi, et al.
Published: (2022-10-01)

Venous thromboembolism in patients with COVID-19. A prevalent and a preventable complication of the pandemic
by: Murtuza Razi, et al.
Published: (2021-05-01)

Optimal duration of anticoagulant therapy in patients with venous thromboembolism
by: Gualtiero Palareti
Published: (2018-09-01)

Chemoprophylactic Anticoagulation 72 Hours After Spinal Fracture Surgical Treatment Decreases Venous Thromboembolic Events Without Increasing Surgical Complications
by: Khaled Taghlabi, et al.
Published: (2022-09-01)

Direct Oral Anticoagulants or Standard Anticoagulant Therapy in Fragile Patients with Venous Thromboembolism
by: Juan J. López-Núñez, et al.
Published: (2019-01-01)

Safe and effective treatment of venous Thromboembolism associated with Cancer: focus on direct Oral Anticoagulants in Asian patients
by: Lai Heng Lee, et al.
Published: (2022-10-01)

Cost-effectiveness of new oral anticoagulants in the treatment and secondary prevention of venous thromboembolism
by: A. V. Rudakova
Published: (2015-11-01)

Oral anticoagulants: Optimizing venous thromboembolism management
by: Fahad A S. Aleidan
Published: (2019-01-01)

Association Between Anticoagulation Outcomes and Venous Thromboembolism History in Chronic Thromboembolic Pulmonary Hypertension
by: Yong-Jian Zhu, et al.
Published: (2021-05-01)

Length of Anticoagulation in Provoked Venous Thromboembolism: A Multicenter Study of How Real‐World Practice Mirrors Guideline Recommendations
by: Elizabeth Joyce, et al.
Published: (2022-11-01)

Direct oral anticoagulants in cancer-associated venous thromboembolism
by: Kirill Lobastov, et al.
Published: (2020-01-01)

Patients with Cushing’s syndrome suffer from provoked venous thromboembolism and are anticoagulated in various patterns
by: Agata Hanna Bryk-Wiązania, et al.
Published: (2024-08-01)

Risk of recurrent venous thromboembolism in cancer patients after discontinuation of anticoagulant therapy
by: Gary E. Raskob
Published: (2024-05-01)

Safety and Efficacy of Rivaroxaban as Extended-Phase Anticoagulation in Patients with Cancer and Venous Thromboembolism: A Preliminary Data Analysis from the Mac Project
by: Enrico Bernardi, et al.
Published: (2022-10-01)

Delayed anticoagulation in venous thromboembolism: Reasons and associated outcomes
by: Nichole E. Brunton, et al.
Published: (2021-05-01)

Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study
by: Elena Campello, et al.
Published: (2020-12-01)

Bleeding and venous thromboembolism events in cancer patients taking direct oral anticoagulants vs. low molecular weight heparin
by: Frank A. Lattuca, et al.
Published: (2023-03-01)

Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores
by: Ramón Lecumberri, et al.
Published: (2021-07-01)

Claims‐Based Score for the Prediction of Bleeding in a Contemporary Cohort of Patients Receiving Oral Anticoagulation for Venous Thromboembolism
by: Alvaro Alonso, et al.
Published: (2021-09-01)

The recent clinical trials on use of the novel direct oral anticoagulants in patients with venous thromboembolism: a review
by: Gualtiero Palareti
Published: (2014-10-01)

A Cross-sectional Study of the Assessment of Venous Thromboembolism Risk and Use of Anticoagulant Thromboprophylaxis
by: Emile Abimana, et al.
Published: (2022-03-01)

Anticoagulation after intracranial hemorrhage in brain tumors: Risk of recurrent hemorrhage and venous thromboembolism
by: Brian J. Carney, et al.
Published: (2020-07-01)

The treatment of venous thromboembolism with new oral anticoagulants
by: Davide Imberti
Published: (2013-12-01)

Clinical Benefits of Oral Anticoagulant Use in Cancer Patients at Increased Risk for Venous Thromboembolism per Khorana Index
by: Choi YJ, et al.
Published: (2021-05-01)

Risk of major bleeding during extended oral anticoagulation in patients with first unprovoked venous thromboembolism: a systematic review and meta-analysis protocol
by: Faizan Khan, et al.
Published: (2019-10-01)

The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment
by: К. V. Lobastov, et al.
Published: (2020-05-01)

Newer oral anticoagulants in venous thromboembolism
by: Sunil Modi, et al.
Published: (2021-01-01)

Factor XI, a potential target for anticoagulation therapy for venous thromboembolism
by: Tingting Li, et al.
Published: (2022-10-01)

Predictors of use of direct oral anticoagulants in patients with venous thromboembolism: Findings from the Registro Informatizado Enfermedad Tromboembólica registry
by: Alicia Lorenzo, et al.
Published: (2022-11-01)

Treatment and secondary prophylaxis of venous thromboembolism with direct oral anticoagulants in patients with severe hereditary thrombophilia
by: Pasquale Madonna, et al.
Published: (2021-03-01)

Efficacy and safety of novel oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolism
by: Maodi Xu, et al.
Published: (2018-09-01)

Population-based study of long-term anticoagulation for treatment and secondary prophylaxis of venous thromboembolism in men with prostate cancer in Sweden
by: Yanina Balabanova, et al.
Published: (2022-02-01)

Preventing venous thromboembolism in oncology practice: Use of risk assessment and anticoagulation prophylaxis
by: Karlyn A. Martin, et al.
Published: (2020-10-01)

ANTICOAGULANT THERAPY OF VENOUS THROMBOEMBOLIC COMPLICATIONS: PROBLEMS AND PERSPECTIVES
by: N. M. Vorobieva, et al.
Published: (2015-03-01)

Risk of intracranial bleeding in patients with primary brain cancer receiving therapeutic anticoagulation for venous thromboembolism: A meta‐analysis
by: Angelo Porfidia, et al.
Published: (2020-06-01)

Recent advances in mechanism and anticoagulant therapy of venous thromboembolism in patients with non-dialysis chronic kidney disease
by: Jia-xin Wang, et al.
Published: (2024-09-01)

Inherited thrombophilia and venous thromboembolism: testing rules in clinical practice
by: I. V. Zotova, et al.
Published: (2020-09-01)